Lv Xiu-He, Wang Chun-Hui, Xie Yan
Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Surg Endosc. 2017 Jan;31(1):49-63. doi: 10.1007/s00464-016-4978-7. Epub 2016 Jun 10.
In recent years, submucosal tunneling endoscopic resection (STER) has emerged as a novel therapeutic endoscopic technique for upper gastrointestinal submucosal tumors (SMTs). The aim of this study was to evaluate the safety and efficacy of STER for upper gastrointestinal SMTs.
A systematic search of both English and Chinese databases was performed until November 15, 2015. Complete resection and en bloc resection rates were considered the primary outcome measures. Prevalence of complications was considered the secondary outcome measure. A random-effects model was used to generate conservative estimates of the prevalence of the main outcome variables. All data analyses were performed using Meta-Analyst software (version beta 3.13).
A total of 28 studies were included in the final meta-analysis. The pooled complete resection and en bloc resection rates were 97.5 % (95 % CI 96.0-98.5 %) and 94.6 % (95 % CI 91.5-96.7 %), respectively. The common complications associated with STER were air leakage symptoms and perforation. The pooled prevalence of air leakage symptoms was 14.8 % (95 % CI 10.5-20.5 %) for subcutaneous emphysema and pneumomediastinum, 6.1 % (95 % CI 4.0-9.0 %) for pneumothorax and 6.8 % (95 % CI 4.7-9.6 %) for pneumoperitoneum. Additionally, the pooled prevalence of perforation was 5.6 % (95 % CI 3.7-8.2 %). Only a few cases of bleeding were reported in two studies.
STER is a highly feasible and safe treatment option for upper gastrointestinal SMTs.
近年来,黏膜下隧道内镜切除术(STER)已成为治疗上消化道黏膜下肿瘤(SMT)的一种新型内镜治疗技术。本研究旨在评估STER治疗上消化道SMT的安全性和有效性。
对英文和中文数据库进行系统检索,直至2015年11月15日。完整切除率和整块切除率被视为主要结局指标。并发症发生率被视为次要结局指标。采用随机效应模型对主要结局变量的发生率进行保守估计。所有数据分析均使用Meta-Analyst软件(版本beta 3.13)。
最终的荟萃分析共纳入28项研究。汇总的完整切除率和整块切除率分别为97.5%(95%CI 96.0 - 98.5%)和94.6%(95%CI 91.5 - 96.7%)。与STER相关的常见并发症为漏气症状和穿孔。皮下气肿和纵隔气肿的漏气症状汇总发生率为14.8%(95%CI 10.5 - 20.5%),气胸为6.1%(95%CI 4.0 - 9.0%),气腹为6.8%(95%CI 4.7 - 9.6%)。此外,穿孔的汇总发生率为5.6%(95%CI 3.7 - 8.2%)。两项研究中仅报告了少数出血病例。
STER是治疗上消化道SMT的一种高度可行且安全的治疗选择。